What You Need to Know About Copay Maximizers

Copay maximizers can be a game-changer for those with high medical bills. They're a type of prescription discount card that can help lower the cost of medications.

These cards work by negotiating discounts with pharmacies and manufacturers, allowing you to pay a lower copay at the pharmacy counter.

Some copay maximizers even offer free trials or no-activation fees, making it easy to try them out.

A copay maximizer is a type of benefit that helps reduce out-of-pocket costs for prescription medications.

It's essentially a program that maximizes the copay amount for certain medications, allowing patients to save money on their prescriptions.

A copay maximizer can be particularly helpful for people taking expensive medications, such as those for chronic conditions like diabetes or rheumatoid arthritis.

In some cases, a copay maximizer can reduce the copay amount to as little as $10 or $20 per prescription.

This can add up to significant savings over time, especially for people taking long-term medication.

A Maximizer Plan is a pharmacy benefit design that includes a Copay Maximizer provision. This type of plan can help patients save money on their prescription medications.

Under a Copay Maximizer program, patients can use any available PAP funds to help cover their cost share of the medication. This means they can get some relief on their copays.

The patient's cost sharing for a specific drug is set at the total annual value of the PAP funds. For example, if a PAP pays $1,200 per year in benefits, the patient's cost sharing would be set at $100 per month.

The PAP payments do not count toward the deductible and out-of-pocket maximums. This means patients are still responsible for those costs, even with the help of the PAP program.

For more insights, see: What Is Copay Assistance Program

Adherence is crucial when taking medication or following a treatment protocol, as it ensures you're taking your medication as prescribed by your doctor.

Cost-sharing is a payment method where you're required to pay a portion of the costs associated with healthcare services or products.

Out-of-pocket costs include copayments, coinsurance, and deductibles, which can add up quickly if you're not prepared.

A deductible is a fixed amount you must pay out-of-pocket before health benefits become payable, usually expressed in terms of an annual amount.

Prior authorization and step therapy are types of utilization management that require health plan approval for certain medications to be covered.

A fresh viewpoint: Do You Pay Copay after Out-of-pocket Maximum Is Met

Adherence is the ability to take a medication or comply with a treatment protocol according to the prescriber's instructions. This is crucial for getting the most out of your medication.

Cost-sharing is a payment method in which you're required to pay some portion of the costs associated with health care services/products. This can include copayments, coinsurance, and deductibles.

Out-of-pocket costs refer to the portion of payments for covered health services required to be paid by the member. This can add up quickly, so it's essential to understand what you're responsible for paying.

You might enjoy: United Healthcare Mental Health Coverage Copay

Patient assistance programs are manufacturer-sponsored programs that provide financial assistance or free drug product to low-income individuals to augment any existing prescription drug coverage. These programs can be a game-changer for those who need help affording medication.

Prior authorization is a type of utilization management that requires health plan approval for members taking certain drugs for a claim to be covered under the terms of the medical or pharmacy benefit. This helps promote the use of medications that are safe, effective, and provide the greatest value.

Specialty medications are high-cost medications that require unique storage/shipment and additional education and support from a healthcare professional. These medications often treat serious, chronic, and life-threatening diseases.

Tiered formularies are a pharmacy benefit design that financially rewards patients for using generic and preferred drugs by requiring progressively higher copayments for progressively higher tiers. This can help you save money on your medication.

On a similar theme: Copay Assistance Program

An Accumulator program is similar to a Copay Maximizer program, but with a key difference in how patient spending contributes to the deductible or out-of-pocket maximum.

In an Accumulator program, the pharma company's PAP payments do not count toward the patient's pharmacy deductible or out-of-pocket maximum.

The patient is responsible for the full cost of the therapy once PAP funds are exhausted, and it's only at that point that patient spending contributes to the deductible or out-of-pocket maximum.

This can be a significant cost burden for patients, as they must pay the full amount upfront before their spending contributes to their deductible or out-of-pocket maximum.

A different take: Difference between Copayment and Deductible

Copay maximizer programs are a type of cost-shifting strategy used by insurance plans to reduce their financial burden. These programs can have a significant impact on a patient's out-of-pocket costs.

Patients may be eligible for manufacturer copay funds, which can cover a portion or all of their copay costs. For example, J.W. in Example 1 can apply for up to $8,000 in manufacturer copay funds per year.

There are several types of programs that can affect a patient's copay costs, including copay accumulator programs, copay maximizer programs, and alternative funding programs (AFPs). AFPs, for instance, can cover a portion or all of a patient's copay costs, as seen in J.W.'s case.

Take a look at this: How Do Copay Assistance Programs Work

To navigate these programs, care teams can provide patient education and resources to help patients understand their benefits design and potential costs. This can include explaining copay accumulator programs, copay maximizer programs, and AFPs.

Care teams can also calculate and communicate patient costs of therapy with and without manufacturer assistance, as seen in Table 2. This can help patients make informed decisions about their treatment options.

Here are some key points to keep in mind when navigating copay maximizer programs:

HFA and coalition allies are advocating for state and federal action to close the "non-EHB loophole" by supporting the bipartisan HELP Copays Act, which would require health plans to count all payments made "by or on behalf" of patients toward patient deductibles and out-of-pocket maximums.

This legislation aims to address the issue of copay maximizers, which can result in patients being responsible for higher costs.

HFA and coalition allies are also asking federal regulators to rein in abusive health plan/middleman strategies, highlighting the need for greater oversight and regulation in this area.

Advocates are pushing for state and federal action to address the "non-EHB loophole." HFA and coalition allies support H.R. 830, the bipartisan HELP Copays Act, which would require health plans to count all payments made "by or on behalf" of patients toward patient deductibles and out-of-pocket costs.

This legislation aims to close the loophole that allows copay maximizers to exploit patients. By counting all payments made by or on behalf of patients, the act would help ensure that patients are not unfairly burdened with high out-of-pocket costs.

Federal regulators are also being asked to rein in abusive health plan/middleman strategies.

High-cost specialty therapies present affordability challenges for insurance plans and patients.

Copay accumulators, copay maximizers, and AFPs are increasingly common in insurance benefit designs, particularly for high-priced specialty medications.

These cost-shifting programs increase administrative workload for care teams.

Many manufacturers have reduced or eliminated patient assistance through copayment assistance or charitable funds for patients on plans using accumulators, maximizers, or AFPs.

Specialty pharmacists, prescribers of specialty medications, and patients must be able to recognize and navigate these programs to ensure timely access to needed specialty medications.

Insurers and employers should consider the risks and potential benefits of copay accumulator and maximizer programs.

They should clearly communicate the use of such programs in their benefit design during the plan's open enrollment period.

Insurers and employers should also be aware of the increased complexity that they introduce for some patients, including challenges with medication adherence for accumulator programs following exhaustion of manufacturer copay support.

Furthermore, insurers and employers should re-evaluate AFPs given the potential for delays or non-initiation of drugs carved out under these programs.

A different take: Copay Accumulator Ban

Copay maximizer strategies are a relatively new tactic used by health insurers to extract the full value from copay assistance programs. They work by labeling certain drugs as "non-essential health benefits" to sidestep Affordable Care Act limits on patient cost-sharing.

This classification has nothing to do with medical necessity, but rather allows health plans to set patient copays far above ACA maximums. The health plan then tells the patient that the only way to avoid inflated cost-sharing amounts is to sign up with a third-party entity, the copay maximizer program.

These stratagems exacerbate financial stress, denying chronic disease patients the ability to benefit from copay assistance programs. Copay maximizers generate confusion, anxiety, and additional red tape for patients to navigate.

Patient copay assistance programs are a lifeline for many in the bleeding disorders community, but that lifeline is fraying.

The first cut came in 2016, when health insurers began implementing copay accumulator adjuster strategies, accepting manufacturer copay assistance but refusing to credit those dollars toward patients’ deductibles and out-of-pocket (OOP) maximums.

As of 2022, many insurers have modified their approach to copay assistance, implementing “copay maximizers” in place of copay accumulator adjusters. These maximizers appeared more often than copay accumulator adjusters in commercial health plans.

If this caught your attention, see: Copay Accumulator Program

Health insurers and their partners now view copay programs as a piggybank, and use maximizers as the tool to extract the full value from that piggybank.

Copay maximizer strategies work by categorizing particular drugs as “non-essential health benefits” (non-EHBs), a classification that has nothing to do with medical necessity.

This scheme allows health plans to sidestep Affordable Care Act limits on patient cost-sharing and siphon off the full amount of copay assistance available from the drug manufacturer.

Copay maximizers can have a significant impact on patients' lives, exacerbating financial stress and making it harder for them to benefit from copay assistance programs.

These complex schemes generate confusion, anxiety, and additional red tape for patients to navigate, making it even more difficult for them to manage their chronic disease.

Patients who rely on copay assistance programs to cope with their high yearly health spending are often left feeling overwhelmed and uncertain about how to navigate these schemes.

Denying patients the ability to benefit from these programs is particularly concerning, given that they were created to help patients in need, not to create more obstacles.